US Stock Market Movement: Recursion surges on October 9 — Tempus contract renewal, ARK increases holdings, and AI drug development

Recursion October 9th Surge Analysis

Keywords: Tempus contract renewal, ARK increased holdings, AI pharmaceuticals

1. On September 15, the company signed an amended master agreement with Tempus AI, extending the data licensing collaboration until 2029. The agreement replaces part of the variable fees with a $42 million committed payment, involving Tempus' multimodal data and the company's TxFM model.

2. On October 6, an ARK fund purchased about 1.48 million shares of Recursion, with a holding value of around $6.1 million. The company recently extended its data licensing collaboration with Tempus until 2029.

3. On September 20, the company presented its end-to-end AI drug discovery platform at the Morgan Stanley Global Healthcare Conference. REC-4881 showed a rapid and sustained reduction in gastrointestinal polyp burden in a Phase II trial. The company is discussing potential registration pathways with the FDA and plans to announce more data in November.

(Disclaimer: This content is summarized from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)